The Correlation between Volatile Organic Compounds (VOC) with Leukotriene B4 and Eosinophil Counts in Chronic Obstructive Pulmonary Disease Patients
DOI:
https://doi.org/10.36408/mhjcm.v11i1.1035Keywords:
Volatile Organic Compounds, Leukotriene B4, Eosinophil, Chronic Obstructive Pulmonary DiseaseAbstract
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a progressive respiratory disorder characterized by increasing Leukotriene B4 (LTB4) and eosinophil counts. Volatile organic compounds (VOCs) have shown promise as non-invasive biomarkers, reflecting COPD pathophysiology. Identifying specific VOCs associated with increased LTB4 and eosinophil counts could lead to the discovery of potential biomarkers for COPD severity or progression.
AIMS: This study aims to investigate the correlation between VOCs and leukotriene B4 (LTB4) levels, as well as eosinophil counts counts in COPD patients.
METHOD: Using an observational-analytic method with a case-control approach, 20 COPD patients and 20 controls were enrolled from the respiratory outpatient department of Dr. Saiful Anwar General Hospital, Malang. VOC levels were measured using a breath analyzer, while LTB4 levels were determined through enzyme-linked immunosorbent assays. Spearman’s correlation tests examined associations between VOCs, LTB4, eosinophil counts, and comorbidity, with Mann-Whitney tests comparing results against the control group. Data significance was set at p < 0.05.
RESULT: There were 40 COPD patients and 40 controls in this study. There were significant differences between VOCs in the COPD group and the control group (p < 0.05). LTB4 level significantly increased in the COPD group than in the control group (p < 0.001), and there was no difference in the eosinophil level. There was a correlation between LTB4 and VOC level of C2H5OH in COPD patients (p = 0.009; r = 0.410). There was no correlation between eosinophil counts and VOCs (p = 0.939). The level of VOCs was significantly different between patients with only COPD and patients with COPD and comorbid lung cancer (p < 0.05).
CONCLUSION: There is a correlation between VOC and LTB4 in COPD patients.
Downloads
References
1. Global strategy for the diagnosis, management, and prevention of Chronic Obstructive Lung Disease. 2021 GOLD Reports - Global Initiative for Chronic Obstructive Lung Disease - GOLD. [Internet]. [cited 2022]. Available from: https://goldcopd.org/2021-gold-reports/
2. Wang C, Zhou J, Wang J, et al. Progress in mechanisms and targeted drug therapy for COPD. Signal Transduction and Targeted Therapy. 2020;5(248):1-20. doi:10.1038/s41392-020-00333-6
3. Republic of Indonesia Ministry of Health. Smoking is the main cause of chronic obstructive pulmonary disease. Ministry of Health of the Republic of Indonesia. 2021.
4. Jareño-Esteban JJ, Muñoz-Lucas MÁ, Gómez-Martín Ó, et al. Study of 5 Volatile Organic Compounds in Exhaled Breath in Chronic Obstructive Pulmonary Disease. Arch Bronconeumol. 2017;53(5):251-256. doi:10.1016/j.arbres.2016.12.006
5. Basanta M, Ibrahim B, Dockry R, et al. Exhaled volatile organic compounds for phenotyping chronic obstructive pulmonary disease: a cross-sectional study. Respiratory research. 2012;13(1):72. doi:10.1186/1465-9921-13-72
6. Mansurova M, Ebert B, Blank L, Ibáñez A. A breath of information: the volatility. Curr Genet. 2018;64(4):959-964. doi:10.1007/s00294-018-0820-2
7. Pizzini A, Filipiak W, Wille J, et al. Analysis of volatile organic compounds in the breath of patients with stable or acute exacerbation of chronic obstructive pulmonary disease. Journal of breath research. 2018;12(3):036002. doi:10.1088/1752-7163/aabeb2
8. Besa V, Teschler H, Kurth I, et al. Exhaled volatile organic compounds discriminate patients with chronic obstructive pulmonary disease from healthy subjects. Int J Chron Obstruct Pulmon Dis. 2015;10:399–406. doi:10.2147/COPD.S77395
9. KaźMierczak M, Ciebiada M, Pękala-Wojciechowska A, et al. Evaluation of Markers of Inflammation and Oxidative Stress in COPD Patients with or without Cardiovascular Comorbidities. Heart, Lung and Circulation. 2015;24(8):817–823. doi:10.1016/j.hlc.2015.03.029
10. Kazeminasab S, Emamalizadeh B, Jouyban A, Shoja MM, Khoubnasabjafari M. Macromolecular biomarkers of chronic obstructive pulmonary disease in exhaled breath condensate. Biomarks. med. 2020;14(11):1047-1064. doi:10.2217/bmm-2020-0025
11. Tashkin DP, Wechsler ME. The role of eosinophils in airway inflammation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2018;13:335–349. doi:10.2147/COPD.S140512
12. Easter M, Bollenbecker S, Barnes JW, Krick S. Targeting Aging Pathways in Chronic Obstructive Pulmonary Disease. Int J Mol Sci. 2020;21(18):6924. doi:10.3390/ijms21186924
13. Kukrety SP, Parekh JD, Bailey KL. Chronic obstructive pulmonary disease and the hallmarks of aging. Lung India : official organ of Indian Chest Society. 2018;35(4):321–327. doi:10.4103/lungindia.lungindia_206_18
14. Zhang H, Wu F, Yi H, et al. Gender Differences in Chronic Obstructive Pulmonary Disease Symptom Clusters. Int J Chron Obstruct Pulmon Dis. 2021;16:1101–1107. doi:10.2147/COPD.S303100
15. Rodrigues SO, Cunha CMCD, Soares GMV, et al. Mechanisms, Pathophysiology and Currently Proposed Treatments of Chronic Obstructive Pulmonary Disease. Pharmaceuticals (Basel, Switzerland). 2021;14(10):979. doi:10.3390/ph14100979
16. Zhang L, Huang J, Dong R, Feng Y, Zhou M. Therapeutic potential of BLT1 antagonist for COPD: involvement of inducing autophagy and ameliorating inflammation. Drug design, development and therapy. 2019;13:3105–3116. doi:10.2147/DDDT.S216787
17. Baker JR, Donnelly LE. Leukocyte Function in COPD: Clinical Relevance and Potential for Drug Therapy. Int J Chron Obstruct Pulmon Dis. 2021;16:2227–2242. doi:10.2147/COPD.S295781
18. Semenzato U, Biondini D, Bazzan E, et al. Low-Blood Lymphocyte Number and Lymphocyte Decline as Key Factors in COPD Outcomes: A Longitudinal Cohort Study. Respiration; international review of thoracic diseases. 2021;100(7):618–630. doi:10.1159/000515556
19. Hikichi M, Mizumura K, Maruoka S, Gon Y. Pathogenesis of chronic obstructive pulmonary disease (COPD) induced by cigarette smoke. Journal of thoracic disease. 2019;11(Suppl 17):S2129–S2140. doi:10.21037/jtd.2019.08.77
20. Keogan S, Alonso T, Sunday S, et al. Project Investigators. TackSHS. A Low-Cost Device for Measurement of Exhaled Breath for the Detection of Obstructive Lung Disease. Biosensors. 2021;12:409. doi:10.3390/bios12030409
21. Ibrahim W, Natarajan S, Wilde M, et al. A systematic review of the diagnostic accuracy of volatile organic compounds in airway diseases and their relation to markers of type-2 inflammation. ERJ open research. 2021;7(3):00030-2021. doi:10.1183/23120541.00030-2021
22. Traphagen N, Tian Z, Allen-Gipson D. Chronic Ethanol Exposure: Pathogenesis of Pulmonary Disease and Dysfunction. Biomolecules. 2015;5(4):2840–2853. doi:10.3390/biom5042840
23. Xu WF, Upur H, Wu YH, et al. Metabolomic changes in patients with chronic obstructive pulmonary disease with abnormal Savda syndrome. Exp Ther Med. 2015;9(2):425–431. doi:10.3892/etm.2014.2105
24. Van Berkel JJ, Dallinga JW, Möller GM, et al. A profile of volatile organic compounds in breath discriminates COPD patients from controls. Respiratory medicine. 2010;104(4):557–563. doi:10.1016/j.rmed.2009.11.017
25. Filipiak W, et al. Dependent of exhaled breath composition on exogenous factors, smoking habits and exposure to air pollutants. J Breath Res. 2012;6:036008. doi:10.1088/1752-7155/6/3/036008
26. Ejazi MA, Shameem M, Bhargava R, et al. Correlation of exhaled carbon monoxide level with disease severity in chronic obstructive pulmonary disease. Indian Lungs. 2018;35(5):401-406. doi:10.4103/ijmr.IJMR_1157_17
27. Andersen ZJ, Jensen SS, Hvidberg M, Ketzel M. Chronic Obstructive Pulmonary Disease and Long-Term Exposure to Traffic-Related Air Pollution: A Cohort Study. Am J Respir Crit Care Med. 2011;183:455-461. doi:10.1164/rccm.201003-0433OC
28. Shahzad AA, Mushtaq S, Waris A, et al. A Low-Cost Device for Measurement of Exhaled Breath for the Detection of Obstructive Lung Disease. Biosensors. 2021;12:409. doi:10.3390/bios12030409
29. Wei X, Ding Q, Yu N, et al. Imaging Features of Chronic Bronchitis with Preserved Ratio and Impaired Spirometry (PRISm). Lung. 2018;196:649-658. doi:10.1007/s00408-018-0144-5
30. Allers M, Langejuergen J, Gaida A, et al. Measurement of exhaled volatile organic compounds from patients with chronic obstructive pulmonary disease (COPD) using closed fas loop GC-IMS and GC-APCI-MS.
31. David B, Bafadhel M, Koenderman L, et al. Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait. Thorax. 2021;76:188-195. doi:10.1136/thoraxjnl-2019-214447
32. Nishimura M, Makita H, Nagai K, et al. Hokkaido COPD Cohort Study Investigators. Annual change in lung function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185(1):44–52. doi:10.1164/rccm.201105-0926OC
33. Papaioannou AI, Kostikas K, Papaporfyriou A, et al. The emphysematous phenotype is characterized by low blood eosinophils: a cross-sectional study. COPD. 2017;14(6):635–643. doi:10.1080/15412555.2017.136613.
Additional Files
Published
How to Cite
Issue
Section
Citation Check
License
Copyright (c) 2024 Andrew Santosa, Ngakan Putu Parsama Putra, Aditya Sri Listyoko, Arinto Yudi Ponco Wardoyo, Nanik Setijowati (Author)
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Copyrights Notice
Copyrights:
Researchers publishing manuscrips at Medica Hospitalis: Journal of Clinical Medicine agree with regulations as follow:
Copyrights of each article belong to researchers, and it is likewise the patent rights
Researchers admit that Medica Hospitalia: Journal of Clinical Medicine has the right of first publication
Researchers may submit manuscripts separately, manage non exclusive distribution of published manuscripts into other versions (such as: being sent to researchers’ institutional repository, publication in the books, etc), admitting that manuscripts have been firstly published at Medica Hospitalia: Journal of Clinical Medicine
License:
Medica Hospitalia: Journal of Clinical Medicine is disseminated based on provisions of Creative Common Attribution-Share Alike 4.0 Internasional It allows individuals to duplicate and disseminate manuscripts in any formats, to alter, compose and make derivatives of manuscripts for any purpose. You are not allowed to use manuscripts for commercial purposes. You should properly acknowledge, reference links, and state that alterations have been made. You can do so in proper ways, but it does not hint that the licensors support you or your usage.
